Clinical trials
Advanced Solid Tumor (Phase 1) clinical trials
Below are recruiting advanced solid tumor (phase 1) clinical trials, each written for real people, not researchers. We’re tracking 516 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06258408RecruitingPhase 1
BB102 for advanced solid tumors that have not responded to treatment
This trial studies a new drug called BB102 that targets a specific protein (FGF19/FGFR4) found on some cancer cells. It is for people with advanced solid tumors, especially liver cancer, who have run out of standard treatment options. The goal is to see if the drug is safe and helps shrink or control the cancer.
Guangzhou, GuangdongAges 18–78 - NCT04939610RecruitingPhase 1/Phase 2
Studying a targeted radiation drug for advanced solid tumors
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
Birmingham, AlabamaAges 18 years+ - NCT07751042RecruitingPhase 1/Phase 2
Study of STX-003 with and without pembrolizumab for advanced solid tumors
This study tests an experimental drug called STX-1, given alone or with another drug that helps the immune system fight cancer. It is for people with advanced solid tumors, especially certain types of lung cancer or melanoma, who have already tried standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT05944224RecruitingPhase 1/Phase 2
SPH4336 for advanced solid tumors with or without immunotherapy
This early-phase study tests SPH4336 alone or combined with an immunotherapy drug called cadonilimab in people with advanced solid cancers that can’t be cured with surgery or local treatments. It aims to find out how safe it is and whether it can shrink tumors or control the disease.
Fuzhou, FujianAges 18–75 - NCT05886920RecruitingPhase 1/Phase 2
Study drug for advanced cancers with specific MAPK changes
This Phase 1/2 study tests a new drug (D3S-002) to see if it can shrink or control advanced cancers that have certain MAPK pathway gene changes. It may help people whose cancer has progressed despite standard treatments, especially in a specific lung cancer group.
Detroit, MichiganAges 18 years+ - NCT07414836RecruitingPhase 1
First test of new drug BG-C0979 for advanced solid tumors
This study tests a new drug called BG-C0979 for advanced solid tumors that have not responded to standard treatments. It may be given alone or with other therapies to see if it can shrink tumors or slow cancer growth.
St Louis, MissouriAges 18 years+ - NCT06992687Enrolling by invitationPhase 1/Phase 2
Study of HB0052 for advanced solid tumors
This trial tests a new drug called HB0052 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for various cancer types.
BeijingAges 18 years+ - NCT06840821RecruitingPhase 1/Phase 2
Testing MB0151 for cancers with somatostatin receptors
This trial tests a new drug, MB0151, for adults with advanced solid tumors that have somatostatin receptors and have not responded to standard treatments. It aims to see if MB0151 is safe and can shrink tumors.
Jinan, ShandongAges 18 years+ - NCT06922357RecruitingPhase 1/Phase 2
Testing HRS-6719 for advanced solid tumors
This trial tests a new drug called HRS-6719 for people with advanced or metastatic solid tumors that have progressed after standard treatments or for which no standard treatment exists. The goal is to see if the drug is safe and effective.
Harbin, HeilongjiangAges 18–75 - NCT06736275RecruitingEarly Phase 1
Testing a new gene therapy for advanced solid tumors
This trial tests an experimental gene therapy called SXRN for people with advanced solid tumors that haven't responded to standard treatments. The study aims to see if it's safe and may help slow the disease.
BeijingAges 18–75 - NCT06694480RecruitingPhase 1
Study of FID-022 for advanced solid tumors
This study tests a new drug called FID-022 for people with advanced solid tumors that have not responded to standard treatments. It may be an option for those who could benefit from irinotecan, a common chemotherapy drug.
Los Angeles, CaliforniaAges 18 years+ - NCT06527300RecruitingPhase 2
Study of NHWD-870 for advanced NUT cancer
This trial tests a new drug called NHWD-870 for people with NUT cancer (a rare cancer linked to a gene change). The goal is to see if the drug can help shrink tumors or slow the cancer's growth.
ChongqingAges 12–75 - NCT06439589RecruitingPhase 1/Phase 2
Drug combo for advanced solid tumors
This trial tests a new combination of two drugs (HRS2398 and Adebrelimab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Zhengzhou, HenanAges 18–75 - NCT06426680RecruitingPhase 1
Study of ILB-3101 for advanced solid tumors
This study tests a new drug, ILB-3101, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
ShanghaiAges 18–80 - NCT06464055RecruitingPhase 1/Phase 2
A study of GQ1010 for advanced solid tumors
This trial tests a new drug called GQ1010 for people with advanced solid tumors that have stopped responding to standard treatments. The drug targets a protein called Trop-2 on cancer cells to try to shrink tumors or slow their growth.
BeijingAges 18 years+ - NCT06475131RecruitingPhase 1
Study of BL-B16D1 for advanced solid tumors
This trial tests a new drug called BL-B16D1 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if this drug is safe and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT06431243RecruitingPhase 1/Phase 2
Purinostat Mesylate for advanced solid tumors
This trial tests a new drug called Purinostat Mesylate, either alone or combined with other drugs, in people with advanced solid tumors (including breast cancer) that have not responded to standard treatments. The goal is to see if the drug can help shrink tumors or slow their growth.
Guanzhou, GuangzhouAges 18–75 - NCT06246071RecruitingPhase 1
TYK-00540 for adults with solid tumors
This trial tests a new drug, TYK-00540, for people with solid tumors that have not responded to or cannot tolerate standard treatments. It also looks at specific types of breast and ovarian cancer.
HefeiAges 18 years+ - NCT06205082Enrolling by invitationPhase 1
Testing LIT-00814 tablets for advanced solid tumors
This trial tests an experimental oral tablet (LIT-00814) for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and to find the best dose.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05923008RecruitingPhase 1/Phase 2
Study of IBI130 for advanced solid tumors
This trial tests IBI130 in people with unresectable, locally advanced, or metastatic solid tumors (cancers that can’t be fully removed by surgery or have spread). It may help find whether the drug is safe and can work against these cancers.
Birtinya, QueenslandAges 18 years+ - NCT05830045RecruitingPhase 1
Testing a new drug for advanced solid tumors
This Phase 1 trial studies QLP2117, a new treatment, in people with advanced solid tumors that have come back or didn’t respond to standard care. It mainly looks at safety and how the body handles the drug, and it may help find a dose worth further study.
GuangzhouAges 18 years+ - NCT06088004RecruitingPhase 1/Phase 2
ABO2011 for advanced solid tumors (phase 1/2)
This trial tests a new investigational drug called ABO2011, which is injected directly into tumors. It is for people with advanced solid tumors that have not responded to previous treatments. The goal is to see if the drug is safe and can help shrink or slow tumor growth.
BeijingAges 18 years+ - NCT05789602RecruitingPhase 1
Study drug for advanced solid tumors in adults
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05841563RecruitingPhase 1
PM54 for advanced solid tumors after limited treatment options
This Phase 1 trial tests PM54, a study drug, in people with advanced (cancer that has spread) solid tumors when standard treatments are no longer working. It focuses on safety and early signs of how well the treatment may work in specific cancer types.
San Antonio, TexasAges 18 years+
Hear when a new Advanced Solid Tumor (Phase 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid tumor (phase 1)?
- Yes. Clin2 currently lists 516 recruiting advanced solid tumor (phase 1) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid tumor (phase 1) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid tumor (phase 1) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.